Astrazeneca (AZN) Minority Interest (2016 - 2026)

Astrazeneca has reported Minority Interest over the past 17 years, most recently at $51.0 million for Q1 2026.

For Q1 2026, Minority Interest fell 44.57% year-over-year to $51.0 million; the TTM value through Mar 2026 reached $51.0 million, down 44.57%, while the annual FY2025 figure was $52.0 million, 5300.0% up from the prior year.
Minority Interest for Q1 2026 was $51.0 million at Astrazeneca, down from $52.0 million in the prior quarter.
Over five years, Minority Interest peaked at $92.0 million in Q1 2025 and troughed at -$1.0 million in Q4 2024.
A 5-year average of $27.9 million and a median of $19.0 million in 2022 define the central range for Minority Interest.
Biggest five-year swings in Minority Interest: tumbled 116.67% in 2024 and later surged 9100.0% in 2025.
Year by year, Minority Interest stood at $5.0 million in 2022, then rose by 20.0% to $6.0 million in 2023, then crashed by 116.67% to -$1.0 million in 2024, then skyrocketed by 5300.0% to $52.0 million in 2025, then fell by 1.92% to $51.0 million in 2026.
Business Quant data shows Minority Interest for AZN at $51.0 million in Q1 2026, $52.0 million in Q4 2025, and $83.0 million in Q3 2025.

Peer Comparison